RIGL
- Rigel Pharmaceuticals, Inc.
()
Overview
Company Summary
Rigel Pharmaceuticals, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases.
The company utilizes its expertise in the field of signaling pathways and protein kinases to develop therapeutic candidates that target specific diseases. Their research and development efforts center around identifying new drug targets and designing compounds that can modulate these targets to achieve desired therapeutic effects.
Rigel Pharmaceuticals has a strong pipeline of potential drug candidates at various stages of development. Their lead product, fostamatinib disodium (Tavalisse), is an oral small molecule inhibitor of spleen tyrosine kinase (SYK), which is approved for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had insufficient response to other treatments.
In addition to their existing products, Rigel Pharmaceuticals continues to explore new drug candidates and expand its therapeutic focus. They collaborate with other pharmaceutical companies and research institutions to harness the latest scientific advancements and accelerate the development of innovative drugs.
Overall, Rigel Pharmaceuticals aims to address unmet medical needs and improve the lives of patients suffering from various diseases through the development of targeted, effective, and safe therapeutic options.